

IN THE CLAIMS

Please amend the claims as follows:

Please amend the claims as follows:

1. (Currently Amended) A method of treating traumatic brain injury in a mammal suffering from traumatic brain injury, comprising administering to the mammal suffering from traumatic brain injury, ~~mammalian G-CSF, human G-CSF, or a protein having at least 90% homology to SEQ ID NO:28 and G-CSF activity, mammalian G-CSF comprising one or more chemical substituents, human G-CSF comprising one or more chemical substituents, mammalian G-CSF fused to a second protein, human G-CSF fused to a second protein or combinations thereof~~ in an amount sufficient to treat the traumatic brain injury; and
- assessing neurological function in the mammal after said administering.
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Original) The method of Claim 1, further comprising administering one or more additional hematopoietic factors.
6. (Original) The method of Claim 5, wherein the additional hematopoietic factors are selected from the group consisting of a macrophage stimulating factor, an interleukin, and erythropoietin.
7. (Original) The method of Claim 6, wherein G-CSF and erythropoietin are administered to the mammal.
8. (Cancelled).

9. (Previously Presented) The method of Claim 1, wherein human G-CSF is administered.
10. (Cancelled).
11. (Cancelled).
12. (Original) The method of Claim 1, which further comprises administering tissue plasminogen activator to the mammal.
13. (Cancelled).
14. (Original) The method of Claim 1, which further comprises administering an anti-apoptotic agent.
15. (Cancelled).
16. (Cancelled).
17. (Cancelled).
18. (Previously Presented) The method of Claim 1, wherein the mammal treated is human.
19. (Currently Amended) The method of Claim 1, wherein the ~~mammalian G-CSF, human G-CSF, or a protein having at least 90% homology to SEQ ID NO:28 and G-CSF activity, mammalian G-CSF comprising one or more chemical substituents, human G-CSF comprising one or more chemical substituents, mammalian G-CSF fused to a second protein, human G-CSF fused to a second protein or combinations thereof~~ is administered by one or more modes of administration selected from the group consisting of direct intracerebral injection, intravenously, intraarterially, orally, and subcutaneously.

Claims 20-104 (Cancelled).

105.(Currently Amended) A method of treating traumatic brain injury in a mammal suffering from traumatic brain injury, comprising intravenously administering to the mammal suffering from traumatic brain injury, ~~mammalian G-CSF, human G-CSF, or a protein having at least 90% homology to SEQ ID NO:28 and G-CSF activity, mammalian G-CSF comprising one or more chemical substituents, human G-CSF comprising one or more chemical substituents, mammalian G-CSF fused to a second protein, human G-CSF fused to a second protein, or combinations thereof~~ in an amount sufficient to treat the traumatic brain injury; and

assessing neurological function in the mammal after said administering.

106. (Currently Amended) The method of Claim 105, comprising intravenously administering ~~mammalian~~ human G-CSF.

107.(Previously Presented) The method of Claim 105, comprising intravenously administering a protein having at least 90% homology to SEQ ID NO:28 and G-CSF activity.

108.(Previously Presented) The method of Claim 105, comprising intravenously administering a protein having at least 95% homology to SEQ ID NO:28 and G-CSF activity.

109.(Cancelled).

110.(Cancelled).

111.(Cancelled).

112.(Cancelled).

113.(Cancelled).